Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Kinase inhibitors are often used as cancer targeting agents for their ability to prevent the activation of cell growth and proliferation signals. Cardiotoxic effects have been identified for some marketed kinase inhibitors that were not detected during clinical trials. We hypothesize that more predictive cardiac functional assessments of kinase inhibitors on human myocardium can be established by combining a high-throughput two-dimensional (2D) screening assay and a high-content three-dimensional (3D) engineered cardiac tissue (Biowire TM) based assay, and using human induced pluripotent stem cell-derived CMs (hiPSC-CMs). A subset (80) of compounds from the GlaxoSmithKline published kinase inhibitor set were tested on hiPSC-CM monolayers and significant effects on cell viability, calcium transients, and contraction frequency were observed. Artificial neural network modelling was then used to analyze the experimental results in an efficient and unbiased manner to select for kinase inhibitors with minimal effects on cell viability and function. Inhibitors of specific interest based on the modeling were evaluated in the 3D Biowire tissues. The three-dimensional Biowire platform eliminated oversensitivity in detecting both Ca 2+ transient amplitude enhancements as well as the acute detrimental effects on cell viability due to the kinase inhibitor application as compared to the monolayer testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This model helps identify cardiotoxic effects for some available kinase inhibitors that were not detected during clinical trials.”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [337]
Experimental — accuracy not yet measuredIn the citing paper
“For example, Conant et al. [337] have developed an artificial neural network model to analyze the experimental results in an efficient and unbiased manner to select kinase inhibitors with maximum efficacy and minimum side effects on cardiac cell viability and function.”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [337]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Agatonovic-Kustrin, S., & Beresford, R. (2000) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(99)00272-1 · Cited by 1,957
Tu, J. V. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00002-9 · Cited by 1,818
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz‐Eldor, J., & Gepstein, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12131 · Cited by 1,814
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112131 · Cited by 1,536
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Self-citationIKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J.-L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 878
Cited by
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Self-citationCardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Self-citation
Metadata
- Authors
- Conant, G., Ahadian, S., Zhao, Y., & Radisic, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Corresponding author
- Radisic, Milica
- Venue
- Scientific Reports
- Published
- 2017-09-18
- Volume
- 7
- Issue
- 1
- Pages
- 11807-11807
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5603510
- OpenAlex
- W2754401477
- Cited by
- 25
- References
- 64
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 9 · 2019: 5 · 2018: 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- California HIV/AIDS Research Program
- National Institutes of Health (2r01hl076485-16, 2R01 HL076485, HL076485)
- Canadian Institutes of Health Research (CHRP-493737-16, MOP-126027 and MOP-137107, 137107_1, 126027_1)
- Natural Sciences and Engineering Research Council of Canada (CHRP 493737-16, RGPIN 326982‐10, 493737-16)
- National Heart, Lung, and Blood Institute (R01-HL076485)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, artificial neural networks, high-content screening, calcium transients, cardiomyocyte contraction, drug repurposing, cardioprotection
- MeSH terms
- Cell Survival, Humans, Myocardium, Neural Networks, Computer, Tissue Engineering, Myocytes, Cardiac, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires. https://app.cochat.ai/papers/10.1038/s41598-017-12048-5
- The paper
- Conant, G., Ahadian, S., Zhao, Y., & Radisic, M. (2017). Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires. Scientific Reports. https://doi.org/10.1038/s41598-017-12048-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.